Levels of Purine, Kynurenine and Lipid Peroxidation Products in Patients with Inflammatory Bowel Disease
The factors affecting gut activity in inflammatory bowel disease are unclear, but purines and kynurenines may be involved in the regulation of neuronal activity and therefore gut motility and secretion. We have measured the serum levels of these compounds in patients and in sex-and age-matched controls. Purines and kynurenines were analysed using HPLC. The levels of tryptophan and its metabolites 3hydroxykynurenine, 3-hydroxyanthranilic acid and xanthurenic acid were unchanged in all patients. However, the levels of kynurenine and kynurenic acid were significantly elevated in patients with inflammatory bowel disease when compared to control subjects. There were no significant differences between patients and controls for any of the purines analysed or for neopterin. In the inflammatory bowel disease patients serum lipid peroxidation products were significantly elevated when compared to control subjects, suggesting the presence of increased oxidative stress consistent with inflammatory activity. The elevated level of kynurenic acid may represent either a compensatory response to elevated activation of enteric neurones, or a primary abnormality, which induces a compensatory increase in gut activity, but may indicate a role for kynurenine modulation of glutamate receptors in the symptoms of inflammatory bowel disease.
KeywordsHPLC Acetonitrile Adenosine Serotonin Neurol
Unable to display preview. Download preview PDF.
- 3.V.H. Hopker, M.J. Saf rey, G. Bumstock, Neurite outgrowth of striatal neurons in vitro: Involvement of purines in the growth-promoting effect of myenteric plexus explants, Intern. J. Develop . Neurosci. 14, 439–451 (1996).Google Scholar
- 5.T.W. Stone, The neuropharmacology of quinolinic and kynurenic acids, Pharmacol. Revs. 45, 309–379 (1993).Google Scholar
- 12.H.E. Shannon, B.D. Sawyer, Glutamate receptors of the NMDA subtype in myenteric plexus of the guinea pig ileum, J. Pharmacol. Exp. Therap. 215, 518–523 (1989).Google Scholar
- 14.D. Fuchs, G. Weiss, G. Reibnegger, H. Wachter, The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases, Crit. Rev. Clin. Lab. Sci,29,307–341 (1992).Google Scholar
- 15.G. Judmaier, P. Meyersbach, G. Weiss, H. Wachter, G. Reibnegger, The role of neopterin in assessing disease activity in Crohn’s disease: classification and regression trees, Amer. J. Grutroentero/. 88, 706–71 I (1993).Google Scholar
- 17.B. Duclos, J.M. Reimund, J.M. Lang, G. Coumaros, P. Chamouard, L. Lehr, R. Baumann, C. Koehl, J.P. Weill, Mononuclear cell activation in Crohn’s disease. Evaluation using serum assay of neopterin and interleukin-2 soluble receptors, Gastroenterol. Gin. Biol. 14,22–27 (1990).Google Scholar
- 22.N.C. Danbolt, Glutamate uptake, Progr . Neurobiol . 65, 1–105 (2001).Google Scholar